PULSE BIOSCIENCES INC (PLSE) — insider trading
Health Care · NASDAQ
PULSE BIOSCIENCES INC (PLSE) has 33 reported SEC Form 4 insider transactions in our data, including 8 open-market purchases and 4 open-market sales among the most recent 33 (latest 2026-09-01).
Recent Form 4 transactions
| Date | Insider | Role | Type | Shares | Price | Value | Filing |
|---|---|---|---|---|---|---|---|
| 2026-09-01 | Teplitsky Liane Rae | Officer (Chief Operating Officer) | Open-market purchase | 1,001 | $49.95 | $50.0K | Form 4 |
| 2026-08-31 | Teplitsky Liane Rae | Officer (Chief Operating Officer) | Open-market purchase | 1,024 | $48.80 | $50.0K | Form 4 |
| 2026-08-28 | Teplitsky Liane Rae | Officer (Chief Operating Officer) | Open-market purchase | 1,034 | $48.35 | $50.0K | Form 4 |
| 2026-08-26 | Teplitsky Liane Rae | Officer (Chief Operating Officer) | Open-market purchase | 1,036 | $48.24 | $50.0K | Form 4 |
| 2026-08-08 | Teplitsky Liane Rae | Officer (Chief Operating Officer) | Grant / award / vesting (derivative) | 700,000 | — | $0 | Form 4 |
| 2026-08-08 | Teplitsky Liane Rae | Officer (Chief Operating Officer) | Grant / award / vesting (derivative) | 200,000 | — | $0 | Form 4 |
| 2026-06-11 | Sainz Maria | Director | Grant / award / vesting (derivative) | 3,793 | — | $0 | Form 4 |
| 2026-06-11 | Sainz Maria | Director | Grant / award / vesting (derivative) | 30,000 | — | $0 | Form 4 |
| 2026-06-11 | Soni Manmeet Singh | Director | Grant / award / vesting (derivative) | 30,000 | — | $0 | Form 4 |
| 2026-06-11 | DUGGAN ROBERT W | Director, 10% owner | Grant / award / vesting (derivative) | 12,495 | — | $0 | Form 4 |
| 2026-06-11 | DUGGAN ROBERT W | Director, 10% owner | Grant / award / vesting (derivative) | 30,000 | — | $0 | Form 4 |
| 2026-06-11 | van den Broek Richard | Director | Grant / award / vesting (derivative) | 8,423 | — | $0 | Form 4 |
| 2026-06-11 | van den Broek Richard | Director | Grant / award / vesting (derivative) | 30,000 | — | $0 | Form 4 |
| 2026-06-11 | Zanganeh Mahkam | Director | Grant / award / vesting (derivative) | 14,504 | — | $0 | Form 4 |
| 2026-06-11 | Zanganeh Mahkam | Director | Grant / award / vesting (derivative) | 30,000 | — | $0 | Form 4 |
| 2026-05-11 | DUGGAN ROBERT W | Director, 10% owner | Open-market purchase | 660,233 | $19.69 | $13.00M | Form 4/A |
| 2026-05-11 | DUGGAN ROBERT W | Director, 10% owner | Open-market purchase | 660,233 | $19.69 | $13.00M | Form 4 |
| 2026-05-11 | LAVIOLETTE PAUL A | Director, Officer (Chief Executive Officer) | Open-market purchase | 15,000 | $19.69 | $295.4K | Form 4 |
| 2026-05-11 | LAVIOLETTE PAUL A | Director, Officer (Chief Executive Officer) | Open-market purchase | 15,000 | $19.69 | $295.4K | Form 4/A |
| 2026-03-23 | UECKER DARRIN | Director, Officer (Chief Technology Officer) | Grant / award / vesting (derivative) | 100,000 | — | $0 | Form 4 |
| 2026-02-18 | Danahy Kevin Patrick | Officer (Chief Commercial Officer) | Option exercise / conversion (derivative) | 5,000 | — | $0 | Form 4 |
| 2026-02-18 | Danahy Kevin Patrick | Officer (Chief Commercial Officer) | Open-market sale | 5,000 | $23.64 | $118.2K | Form 4 |
| 2026-02-18 | Danahy Kevin Patrick | Officer (Chief Commercial Officer) | Option exercise / conversion | 5,000 | $1.53 | $7.7K | Form 4 |
| 2026-02-17 | Danahy Kevin Patrick | Officer (Chief Commercial Officer) | Option exercise / conversion (derivative) | 20,000 | — | $0 | Form 4 |
| 2026-02-17 | Danahy Kevin Patrick | Officer (Chief Commercial Officer) | Open-market sale | 20,000 | $23.63 | $472.6K | Form 4 |
| 2026-02-17 | Danahy Kevin Patrick | Officer (Chief Commercial Officer) | Option exercise / conversion | 20,000 | $1.53 | $30.6K | Form 4 |
| 2026-02-13 | Danahy Kevin Patrick | Officer (Chief Commercial Officer) | Option exercise / conversion (derivative) | 20,000 | — | $0 | Form 4 |
| 2026-02-13 | Danahy Kevin Patrick | Officer (Chief Commercial Officer) | Open-market sale | 20,000 | $23.53 | $470.6K | Form 4 |
| 2026-02-13 | Danahy Kevin Patrick | Officer (Chief Commercial Officer) | Option exercise / conversion | 20,000 | $1.53 | $30.6K | Form 4 |
| 2026-02-12 | Danahy Kevin Patrick | Officer (Chief Commercial Officer) | Option exercise / conversion (derivative) | 20,000 | — | $0 | Form 4 |
| 2026-02-12 | Danahy Kevin Patrick | Officer (Chief Commercial Officer) | Open-market sale | 20,000 | $23.37 | $467.4K | Form 4 |
| 2026-02-12 | Danahy Kevin Patrick | Officer (Chief Commercial Officer) | Option exercise / conversion | 20,000 | $1.53 | $30.6K | Form 4 |
| 2025-02-03 | Skinner Jon | Officer (Chief Financial Officer) | Grant / award / vesting (derivative) | 300,000 | — | $0 | Form 4 |
Ask the chat about PLSE's insider activity →
Transaction types are the SEC Form 4 codes: open-market purchases (P) and sales (S) are the only rows that reflect open-market conviction. Awards/vesting (A), option exercises (M/X/C), shares withheld for taxes (F) and gifts (G) are compensation or mechanical, not buying or selling on the open market. Sales may be planned and non-discretionary (e.g. a Rule 10b5-1 plan); open-market buying is not a recommendation to buy. Informational only — not financial advice.
Source: SEC EDGAR Form 3/4/5. See the full company profile: PULSE BIOSCIENCES INC (PLSE).
Last updated 2026-09-01 (most recent filing date).
Informational only — NOT financial advice. Insider filings are sourced from SEC EDGAR and shown with their reported dates.